Stocktoria
BIODESIX INC BDSX
Nasdaq · stock · Services-Medical Laboratories · website · IPO 2020-10-28
BIODESIX INC financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $88.5M | $71.3M | $49.1M | $38.2M | $54.5M | $45.6M | $24.6M |
| R&D expense | $12.0M | $9.6M | $10.0M | $13.1M | $12.8M | $10.8M | $10.5M |
| SG&A expense | $87.5M | $80.5M | $67.4M | $61.5M | $50.5M | $34.9M | $30.6M |
| Operating income | -$27.9M | -$34.5M | -$41.3M | -$50.6M | -$40.9M | -$22.9M | -$26.7M |
| Interest expense | $7.7M | $8.3M | $9.5M | $8.1M | $4.5M | $7.6M | $3.0M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$35.3M | -$42.9M | -$52.1M | -$65.4M | -$43.2M | -$65.4M | -$30.7M |
| EPS (diluted) | $-4.67 | $-6.64 | $-0.64 | $-1.55 | $-1.58 | — | — |
| Operating cash flow | -$23.3M | -$48.6M | -$22.9M | -$45.0M | -$28.2M | -$21.4M | -$21.7M |
| Free cash flow | -$23.5M | -$51.9M | -$45.8M | -$48.3M | -$30.5M | -$23.3M | -$23.0M |
| Cash & equivalents | $19.0M | $26.2M | $26.3M | $43.1M | $32.7M | $62.1M | $5.3M |
| Total assets | $87.5M | $97.2M | $99.1M | $92.9M | $76.1M | $121.1M | $45.0M |
| Total liabilities | $89.9M | $76.4M | $94.5M | $72.3M | $56.4M | $79.9M | $76.2M |
| Shareholders' equity | -$2.5M | $20.9M | $4.6M | $20.6M | $19.7M | $41.2M | -$225.1M |
Growth · year-over-year · Revenue CAGR 23.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +24.1% | +45.3% | +28.5% | -29.9% | +19.6% | +85.6% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.